Eckert & Ziegler BEBIG GmbH and TCL Healthcare Equipment (Shanghai) Co., Ltd signed a joint venture agreement to enter the High Dose Rate Brachytherapy solutions market in China.

The parties will develop, manufacture and distribute an HDR afterloader for the Chinese market. The joint venture will trade under the name TCL Eckert & Ziegler BEBIG Healthcare (Wuxi) Co. Ltd. and is owned 51% by TCL Healthcare Equipment (Shanghai) Co., Ltd. and 49% by Eckert & Ziegler BEBIG GmbH.

TCL Healthcare Equipment (Shanghai) Co., Ltd. is part of the TCL Healthcare Group (a listed Chinese company) and Eckert & Ziegler BEBIG GmbH is part of Eckert & Ziegler AG.

http://sea.tclmedical.com/gongsixinwen/20190801159.html 

About TCL Healthcare Equipment (Shanghai) Co., Ltd. (TCL Healthcare Equipment)

TCL Healthcare Group, established in 2009, is one of the leading suppliers of healthcare diagnostic imaging products in China and a provider of  third-party imaging services.

About Eckert & Ziegler BEBIG GmbH (Eckert & Ziegler BEBIG)

Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry. Its core business is the production and distribution of medical products for the treatment of cancer using brachytherapy. The company headquarters are in Germany, with production facilities in Germany and in the USA, as well as offices throughout Europe, Asia and the USA. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing and distribution of its product line. The company’s products and equipment are intended for use by oncologists, radiotherapists, urologists, ophthalmologists and medical physicists.

Buchang held its 2017 Annual Shareholder Meeting in June 2018, where it approved the payment of its FY2017 dividend and announced a bonus share issue. Details of these are set out below:

– Dividend: FY2017 profit distribution plan of RMB1.614 per share (before tax)
– Bonus Share: the issuance of 3 new shares for every 10 existing shares held

In addition, the Company also finalised its FY2018 budget as follows:

– revenue of RMB16.2 billion (a 16.8% increase Y-o-Y), and
– net profit of RMB1.8 billion (a 9.8% increase Y-o-Y)

About Buchang

Buchang Pharmaceuticals is one of the leading traditional Chinese medicine (TCM) companies in China. Buchang was founded in 1993 by Mr. Zhao Buchang and his eldest son, Mr. Zhao Tao. Starting as a small TCM drug manufacturer, Buchang has evolved into a sales and marketing powerhouse. The Company has the most extensive sales network amongst its peers in China, covering over 15,000 hospitals and 150,000 drug stores. The Company’s product portfolio consists of in-house developed products, as well as products that it acquired and turned into blockbusters. Buchang’s brand name is widely recognized by physicians and patients throughout China.

Buchang held its 2016 Annual Shareholder Meeting in May 2017, where it approved the payment of its FY2016 dividend. The Company will distribute a total cash dividend of RMB 1.1 billion, or RMB 16.14 for every 10 shares held (before tax). The dividend is expected to be distributed in July 2017.

About Buchang

Buchang Pharmaceuticals is one of the leading traditional Chinese medicine (TCM) companies in China. Buchang was founded in 1993 by Mr. Zhao Buchang and his eldest son, Mr. Zhao Tao. Starting as a small TCM drug manufacturer, Buchang has evolved into a sales and marketing powerhouse. The Company has the most extensive sales network amongst its peers in China, covering over 15,000 hospitals and 150,000 drug stores. The Company’s product portfolio consists of in-house developed products, as well as products that it acquired and turned into blockbusters. Buchang’s brand name is widely recognized by physicians and patients throughout China.

Dongcheng, a pharmaceutical company listed on the A-share market (SZSE:002675), signed an agreement  to acquire 100% of the outstanding shares of AMS in May 2017. The transaction values AMS at a valuation of RMB1.6 billion, which is equivalent to a FY2016 P/E multiple of 24.4x.

According to the agreement, SKR expects to receive a cash payment for 50% of its shareholding on completion of the transaction based on a valuation of RMB1.6 billion, and an additional cash payment for the remaining 50% shareholding at the fair market valuation of AMS based on FY2019’s audited financial statements.

About AMS

Advanced Medical Systems Limited provides radiopharmaceuticals to hospitals and imaging centres for use in Positron Emission Tomography (“PET”) scanners and Positron Emission Tomography / Computed Tomography (“PET/CT”) scanners. The Company is the #1 player in China in the positron radiopharmaceutical industry and one of only two companies licensed to produce and sell Fluorodeoxy- glucose (F18-FDG), which is used in PET/CT scanners. AMS also distributes cyclotrons and provides maintenance services for nuclear medicine equipment.

We are delighted to announce that Buchang completed its A-share IPO on 18 November 2016. The Company listed on the main board of the Shanghai Stock Exchange under the ticker symbol 603858. A link to the news story on the Company’s website can be found here and a link to Buchang’s share price quote can be found here (Bloomberg).

About Buchang Pharmaceuticals

Buchang Pharmaceuticals is one of the leading traditional Chinese medicine (TCM) companies in China. Buchang was founded in 1993 by Mr. Zhao Buchang and his eldest son, Mr. Zhao Tao. Starting as a small TCM drug manufacturer, Buchang has evolved into a sales and marketing powerhouse. The Company has the most extensive sales network amongst its peers in China, covering over 15,000 hospitals and 150,000 drug stores. The Company’s product portfolio consists of in-house developed products, as well as products that it acquired and turned into blockbusters. Buchang’s brand name is widely recognized by physicians and patients throughout China.

We are very happy to report that Buchang Pharmaceuticals, China’s leading private traditional Chinese medicine company and a HAO II portfolio company, received listing approval from the China Securities Regulatory Commission (“CSRC”) on 13 July for its planned A-share IPO.

A link to the announcement on the CSRC’s website (in Chinese) can be found here.

March 29, 2016 – Billings, MT — LP Amina presented its proprietary technology, BenePlus, on the opening day of the Montana Energy Conference.

Detailed coverage can be found on the Billings Gazette.

About LP Amina

LP Amina is a multinational environmental engineering company with offices in China and the United States. The company was founded in 2007 and since then has evolved from being a niche supplier of advanced pollution control technologies to Chinese coal-fired power plants to an integrated clean energy solutions provider to a wide range of industries globally, including gas-fired power generation, cement, pulp and paper and industrial chemicals. LP Amina’s technology platform consists of poly-generation solutions that co-produce electric power and high-value chemicals and synthetic crude oil, bringing industries together to maximize the efficient use of world’s natural resources.

About the Montana Energy Conference

The Montana Energy Conference is held annually and consists of education sessions and discussions with energy professionals, policy and decision makers at all levels, contractors and associated industry professionals. The event provides an all-encompassing look at Montana’s energy potential.

This news story was original posted on the LP Amina company website here.

Investment to Drive Further Development in DJ HealthUnion’s Health Information Exchange Solutions Technology

Shanghai, Beijing and Hong Kong, 16 Sept 2015 – HAO Capital, the China-focused private equity firm, today announced that it has invested USD 12.5 million in DJ HealthUnion Systems Corporation (“DJ HealthUnion”), a leading domestic provider of digital hospital solutions, with a focus on health data sharing solutions. The financing will be used to further support DJ HealthUnion’s development of its interoperable Health Information Exchange (“HIE”) system.

The investment has been made from HAO’s US$73 million Auxiliary Fund, which was launched in 2014.

DJ HealthUnion has become one of the most established healthcare IT companies in China since its inception in 1999. HAO Capital first invested in DJ HealthUnion in 2010.

With financing and operational support from HAO, DJ HealthUnion has successfully expanded its business from Medical Imaging Informatics to a full range of digital hospital solutions, and developed an IP-protected Health Information Exchange (“HIE”) Solution called the Health Information Union Platform (“HiUP”) series. HiUP meets the national and global standards of healthcare IT (“HCIT”) interoperability, a foundation enabling different IT system software applications to exchange information and then meaningfully use the information received.

Qian Weijia, General Manager and CEO of DJ HealthUnion, said, “More and more hospitals in China have multiple HCIT systems, which hold valuable clinical data but simply cannot share it with each other to support clinical decision-making, coordinated care, quality improvement and efficiency. The need for effective data sharing within and among hospitals has rapidly increased in recent years. HiUP is the first HIE system developed in China that can best meet such needs. Mobile and big data applications in the healthcare industry have also become new drivers of health data sharing, which has created even greater potential for HiUP.

“Our self-developed HiUP series of HIE solutions have been successfully applied by some of the leading hospitals and regional union projects in Guangzhou, Suzhou, Shanghai, Beijing and Jinan. With further support from HAO Capital, we are confident of increasing our technical and implementation capability for a nationwide client base, with a mission to provide cost efficient solutions to healthcare providers and to create a better patient experience.”

Elaine Wong, Partner and Co-Founder of HAO Capital, said, “DJ HealthUnion is unique in China, bringing together a team of Healthcare, Hospital Management, and IT experts and we are delighted to be funding its further development. Its HiUP is the first full HIE system in China providing hospital administrators with a real-time dashboard to understand and improve the speed, quality, safety, and cost of hospital-wide patient care. It also enables doctors to secure real-time access to patient data, not only providing information at their fingertips, but directly improving the speed and efficiency of patient care.”

DJ HealthUnion’s unique HiUP system has helped the First Affiliated Hospital of Sun Yat-sen University in Guangzhou fully digitalize its medical records and enabled the hospital to efficiently use all patient information across the various different departments within the hospital. It has not only revolutionized its data management but has also laid the foundation for the hospital to conduct in-depth data analysis in the future.

DJ HealthUnion is part of SKR, HAO Capital’s medical technology platform company. The company’s vision is to become a leading medical equipment, service and solution provider that makes quality healthcare accessible and affordable to patients in China.

SKR has made three key investments to date: AMS (a radiopharmaceutical provider), TCL Healthcare (a medical diagnostic imaging company), and DJ HealthUnion.